We are live on ! Find out more
RHJA

Rice Hall James & Associates Portfolio holdings

AUM $2.05B
1-Year Est. Return 43.16%
This Fund
S&P 500
This Quarter Est. Return
+6.11%
1 Year Est. Return
+43.16%
3 Year Est. Return
+139.79%
5 Year Est. Return
+169.96%
10 Year Est. Return
+906.29%
AUM
$1.82B
AUM Growth
-$26.9M
Cap. Flow
-$65.9M
Cap. Flow %
-3.62%
Top 10 Hldgs %
25.49%
Holding
265
New
15
Increased
38
Reduced
176
Closed
16

Top Buys

Rank Stock Value
1
FOUR icon
Shift4
FOUR
+$20.4M
2
LKQ icon
LKQ Corp
LKQ
+$13.6M
3
PRLB icon
Protolabs
PRLB
+$5.49M
4
GNTX icon
Gentex
GNTX
+$5.07M
5
PRMB
Primo Brands
PRMB
+$4.23M

Top Sells

Rank Stock Value
1
LRN icon
Stride
LRN
+$15.4M
2
YOU icon
Clear Secure
YOU
+$9.41M
3
SITM icon
SiTime
SITM
+$7.56M
4
MGPI icon
MGP Ingredients
MGPI
+$6.55M
5
DOCS icon
Doximity
DOCS
+$6.52M

Sector Composition

Rank Sector Weight
1 Healthcare 30.8%
2 Technology 27.79%
3 Industrials 15.49%
4 Communication Services 7.19%
5 Consumer Discretionary 6.77%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake
Capital Flow
VMC icon
201
Vulcan Materials
VMC
$36.9B
$1.12M 0.06%
4,354
-123
-3% -$33.1K
DOV icon
202
Dover
DOV
$28.4B
$1.1M 0.06%
5,862
-29
-0.5% -$5.67K
MXCT icon
203
MaxCyte
MXCT
$126M
$1.1M 0.06%
+263,833
New +$997K
VRDN icon
204
Viridian Therapeutics
VRDN
$2.67B
$1.02M 0.06%
+53,375
New +$1.16M
IWC icon
205
iShares Micro-Cap ETF
IWC
$1.5B
$997K 0.05%
+7,645
New +$995K
AVNS
206
DELISTED
Avanos Medical
AVNS
$989K 0.05%
+62,129
New +$1.23M
YMAB
207
DELISTED
Y-mAbs Therapeutics
YMAB
$850K 0.05%
108,549
-135
-0.1% -$1.64K
CIEN icon
208
Ciena
CIEN
$58.4B
$840K 0.05%
9,904
-246
-2% -$17.7K
ABBV icon
209
AbbVie
ABBV
$435B
$836K 0.05%
4,707
TDY icon
210
Teledyne Technologies
TDY
$32B
$827K 0.05%
1,781
-3
-0.2% -$1.4K
TECH icon
211
Bio-Techne
TECH
$11.3B
$722K 0.04%
10,020
-4
-0% -$294
IEX icon
212
IDEX
IEX
$17.3B
$701K 0.04%
3,349
-13
-0.4% -$2.85K
EXEL icon
213
Exelixis
EXEL
$13.4B
$687K 0.04%
20,628
-138
-0.7% -$4.48K
BRK.A icon
214
Berkshire Hathaway Class A
BRK.A
$1.12T
$681K 0.04%
1
AAPL icon
215
Apple
AAPL
$4.57T
$629K 0.03%
2,510
BRKR icon
216
Bruker
BRKR
$8.14B
$599K 0.03%
10,210
-5
-0% -$295
KEX icon
217
Kirby Corp
KEX
$6.93B
$590K 0.03%
5,574
-25
-0.4% -$3.01K
EBAY icon
218
eBay
EBAY
$49.8B
$578K 0.03%
9,338
TFX icon
219
Teleflex
TFX
$5.98B
$574K 0.03%
3,224
-4,802
-60% -$986K
ABT icon
220
Abbott
ABT
$187B
$566K 0.03%
5,008
LUCK
221
Lucky Strike Entertainment
LUCK
$911M
$561K 0.03%
+56,055
New +$643K
DENN
222
DELISTED
Denny's
DENN
$554K 0.03%
91,560
-1,880
-2% -$12K
CR icon
223
Crane Co
CR
$12.7B
$543K 0.03%
3,581
-1,186
-25% -$196K
ICLR icon
224
Icon
ICLR
$12.7B
$522K 0.03%
2,491
-4,382
-64% -$1.02M
CDW icon
225
CDW
CDW
$17B
$519K 0.03%
2,981
-29
-1% -$5.63K

Similar funds

Rice Hall James & Associates's Q4 2024 Portfolio in Review

As of Q4 2024, Rice Hall James & Associates held 265 positions worth $1.82B, down 1.5% from $1.85B the previous quarter. Its ten largest holdings account for 25% of the portfolio.

Rice Hall James & Associates withdrew a net $65.9M in Q4 2024, closing 16 positions and reducing 176 holdings. Its most notable exit was SiTime, an estimated $7.56M position sold in full.

By sector, the portfolio is most concentrated in Healthcare at 31% of assets, up from 31% a quarter earlier, followed by Technology and Industrials.

Against the trend, Rice Hall James & Associates opened a new position in Protolabs worth $5.97M.

  • Rice Hall James & Associates's largest Q4 2024 buy was Protolabs: 152,783 shares worth $5.97M.
  • Rice Hall James & Associates added most to Shift4 in Q4 2024, an estimated $20.4M increase.
  • Rice Hall James & Associates's biggest Q4 2024 reduction was Stride, cutting an estimated $15.4M.
  • Rice Hall James & Associates fully exited SiTime in Q4 2024, selling an estimated $7.56M.
  • Rice Hall James & Associates's ten largest holdings make up 25% of its $1.82B portfolio in Q4 2024.
  • Rice Hall James & Associates opened 15 new positions and closed 16 in Q4 2024.
  • Rice Hall James & Associates's portfolio value fell 1.5% quarter-over-quarter to $1.82B.

Based on Rice Hall James & Associates's 13F filing for Q4 2024, filed 31 Jan 2025.